nach oben

Erschienen in:

23.03.2020 | Meta-Analysis

Effect of subclinical hyperthyroidism on osteoporosis: A meta-analysis of cohort studies

verfasst von: Ningning Xu, Yaxian Wang, Yuying Xu, Lishan Li, Jiaqi Chen, Xudong Mai, Jie Xu, Zhen Zhang, Rui Yang, Jia Sun, Hong Chen, Rongping Chen

Erschienen in: Endocrine | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

The effect of subclinical hyperthyroidism (SH) on bone mineral density (BMD) remains unclear, as do the linking mechanisms. This review aims to investigate the relationship between SH and bone loss in terms of the gender-dependent effects of SH on BMD.

Methods

The PUBMED, EMBASE, OVID, MEDLINE, SINOMED and COCHRANE LIBRARY databases (inception to August 12, 2019) were searched for cohort studies investigating the effects of SH on BMD. Eligible studies were subjected to qualitative and quantitative analysis using a random-effects model meta-analysis with the Cochrane systematic evaluation method.

Results

Twelve cohort studies involving 275,086 participants who were followed for 3 months to 13 years were included based on predefined inclusion and exclusion criteria. The results indicated that SH did not affect lumbar spine BMD in females or males. However, a significant reduction in femoral neck BMD was observed in females, but not in males. Further, there was a significant increase in hip fractures events in both females and males with SH.

Conclusions

The present findings indicate that SH is significantly associated with hip fracture risk, and therefore, it is important to assess the risk of fractures in patients with SH. Future studies should focus on methods for accurately determining this risk in patients with SH and providing them with timely and efficient diagnosis and treatment.

Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6), 785–795 (2001). https://doi.org/10.1001/jama.285.6.785 CrossRef

D.L. Glaser, F.S. Kaplan, Osteoporosis. Definition and clinical presentation. Spine 22(24 Suppl.), 12S–16S (1997). https://doi.org/10.1097/00007632-199712151-00003 CrossRefPubMed

N.E. Lane, Epidemiology, etiology, and diagnosis of osteoporosis. Am. J. Obstet. Gynecol. 194(2 Suppl.), S3–S11 (2006). https://doi.org/10.1016/j.ajog.2005.08.047 CrossRefPubMed

B.L. Riggs, L.J. Melton III, The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl.), 505S–511S (1995). https://doi.org/10.1016/8756-3282(95)00258-4 CrossRefPubMed

T. Coughlan, F. Dockery, Osteoporosis and fracture risk in older people. Clin. Med. 14(2), 187–191 (2014). https://doi.org/10.7861/clinmedicine.14-2-187 CrossRef

M. Srivastava, C. Deal, Osteoporosis in elderly: prevention and treatment. Clin. Geriatr. Med. 18(3), 529–555 (2002). https://doi.org/10.1016/s0749-0690(02)00022-8 CrossRefPubMed

D.K. Dhanwal, E.M. Dennison, N.C. Harvey, C. Cooper, Epidemiology of hip fracture: worldwide geographic variation. Indian J. Orthop. 45(1), 15–22 (2011). https://doi.org/10.4103/0019-5413.73656 CrossRefPubMedPubMedCentral

M.T. Drake, B.L. Clarke, E.M. Lewiecki, The pathophysiology and treatment of osteoporosis. Clin. Ther. 37(8), 1837–1850 (2015). https://doi.org/10.1016/j.clinthera.2015.06.006 CrossRefPubMed

J.A. Kanis, O. Johnell, Requirements for DXA for the management of osteoporosis in Europe. Osteoporos. Int. 16(3), 229–238 (2005). https://doi.org/10.1007/s00198-004-1811-2 CrossRefPubMed

10.

N.F. Ray, J.K. Chan, M. Thamer, L.J. Melton III, Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res. 12(1), 24–35 (1997). https://doi.org/10.1359/jbmr.1997.12.1.24 CrossRefPubMed

11.

G.R. Emkey, S. Epstein, Secondary osteoporosis: pathophysiology & diagnosis. Best practice & research. Clin. Endocrinol. Metab. 28(6), 911–935 (2014). https://doi.org/10.1016/j.beem.2014.07.002 CrossRef

12.

D.C. Bauer, B. Ettinger, M.C. Nevitt, K.L. Stone, Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 134(7), 561–568 (2001). https://doi.org/10.7326/0003-4819-134-7-200104030-00009 CrossRefPubMed

13.

M.R. Blum, D.C. Bauer, T.H. Collet, H.A. Fink, A.R. Cappola, B.R. da Costa, C.D. Wirth, R.P. Peeters, B.O. Asvold, W.P. den Elzen, R.N. Luben, M. Imaizumi, A.P. Bremner, A. Gogakos, R. Eastell, P.M. Kearney, E.S. Strotmeyer, E.R. Wallace, M. Hoff, G. Ceresini, F. Rivadeneira, A.G. Uitterlinden, D.J. Stott, R.G. Westendorp, K.T. Khaw, A. Langhammer, L. Ferrucci, J. Gussekloo, G.R. Williams, J.P. Walsh, P. Juni, D. Aujesky, N. Rodondi, Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313(20), 2055–2065 (2015). https://doi.org/10.1001/jama.2015.5161 CrossRefPubMedPubMedCentral

14.

M.I. Surks, E. Ortiz, G.H. Daniels, C.T. Sawin, N.F. Col, R.H. Cobin, J.A. Franklyn, J.M. Hershman, K.D. Burman, M.A. Denke, C. Gorman, R.S. Cooper, N.J. Weissman, Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291(2), 228–238 (2004). https://doi.org/10.1001/jama.291.2.228 CrossRefPubMed

15.

H. Gharib, R.M. Tuttle, H.J. Baskin, L.H. Fish, P.A. Singer, M.T. McDermott, Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J. Clin. Endocrinol. Metab. 90(1), 581–585 (2005). https://doi.org/10.1210/jc.2004-1231. discussion 586–587CrossRefPubMed

16.

B. Biondi, D.S. Cooper, The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29(1), 76–131 (2008). https://doi.org/10.1210/er.2006-0043 CrossRefPubMed

17.

R.S. Bahn Chair, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6), 593–646 (2011). https://doi.org/10.1089/thy.2010.0417 CrossRefPubMed

18.

J.L. Reverter, S. Holgado, N. Alonso, I. Salinas, M.L. Granada, A. Sanmarti, Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr.-Relat. Cancer 12(4), 973–981 (2005). https://doi.org/10.1677/erc.1.01072 CrossRefPubMed

19.

A. Gurlek, O. Gedik, Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 9(6), 539–543 (1999). https://doi.org/10.1089/thy.1999.9.539 CrossRefPubMed

20.

A. Leader, R.H. Ayzenfeld, M. Lishner, E. Cohen, D. Segev, D. Hermoni, Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years. J. Clin. Endocrinol. Metab. 99(8), 2665–2673 (2014). https://doi.org/10.1210/jc.2013-2474 CrossRefPubMed

21.

L.A. Stewart, M. Clarke, M. Rovers, R.D. Riley, M. Simmonds, G. Stewart, J.F. Tierney, Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD statement. JAMA 313(16), 1657–1665 (2015). https://doi.org/10.1001/jama.2015.3656 CrossRefPubMed

22.

G.A.S.B. Wells, D. O’Connell, J. Peterson, V. Welch et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa Health Research Institute (2011). www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Oct 20, 2011

23.

T. Saler, S. Ahbab, Z.A. Saglam, S.O. Keskek, S. Kurnaz, Endogenous subclinical hyperthyroidism may not lead to bone loss in premenopausal women. Hippokratia 18(3), 240–244 (2014)PubMedPubMedCentral

24.

R. Siru, H. Alfonso, S.A.P. Chubb, J. Golledge, L. Flicker, B.B. Yeap, Subclinical thyroid dysfunction and circulating thyroid hormones are not associated with bone turnover markers or incident hip fracture in older men. Clin. Endocrinol. 89(1), 93–99 (2018). https://doi.org/10.1111/cen.13615 CrossRef

25.

B. Abrahamsen, H.L. Jorgensen, A.S. Laulund, M. Nybo, T.H. Brix, L. Hegedus, Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort. J. Bone Miner. Res. 29(9), 2040–2050 (2014). https://doi.org/10.1002/jbmr.2244 CrossRefPubMed

26.

T. Vadiveloo, P.T. Donnan, L. Cochrane, G.P. Leese, The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J. Clin. Endocrinol. Metab. 96(5), 1344–1351 (2011). https://doi.org/10.1210/jc.2010-2693 CrossRefPubMed

27.

I. Sugitani, Y. Fujimoto, Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 150(6), 1250–1257 (2011). https://doi.org/10.1016/j.surg.2011.09.013 CrossRefPubMed

28.

A.C. Waring, S. Harrison, H.A. Fink, M.H. Samuels, P.M. Cawthon, J.M. Zmuda, E.S. Orwoll, D.C. Bauer, A prospective study of thyroid function, bone loss, and fractures in older men: The MrOS study. J. Bone Miner. Res. 28(3), 472–479 (2013). https://doi.org/10.1002/jbmr.1774 CrossRefPubMedPubMedCentral

29.

C. Marcocci, F. Golia, E. Vignali, A. Pinchera, Skeletal integrity in men chronically treated with suppressive doses of l-thyroxine. J. Bone Miner. Res. 12(1), 72–77 (1997). https://doi.org/10.1359/jbmr.1997.12.1.72 CrossRefPubMed

30.

M.C. Garin, A.M. Arnold, J.S. Lee, J. Robbins, A.R. Cappola, Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J. Clin. Endocrinol. Metab. 99(8), 2657–2664 (2014). https://doi.org/10.1210/jc.2014-1051 CrossRefPubMedPubMedCentral

31.

J.S. Lee, P. Buzkova, H.A. Fink, J. Vu, L. Carbone, Z. Chen, J. Cauley, D.C. Bauer, A.R. Cappola, J. Robbins, Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch. Intern. Med. 170(21), 1876–1883 (2010). https://doi.org/10.1001/archinternmed.2010.424 CrossRefPubMedPubMedCentral

32.

R.W. Flynn, S.R. Bonellie, R.T. Jung, T.M. MacDonald, A.D. Morris, G.P. Leese, Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J. Clin. Endocrinol. Metab. 95(1), 186–193 (2010). https://doi.org/10.1210/jc.2009-1625 CrossRefPubMed

33.

W.Y. Lee, K.W. Oh, E.J. Rhee, C.H. Jung, S.W. Kim, E.J. Yun, H.J. Tae, K.H. Baek, M.I. Kang, M.G. Choi, H.J. Yoo, S.W. Park, Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch. Med. Res. 37(4), 511–516 (2006). https://doi.org/10.1016/j.arcmed.2005.09.009 CrossRefPubMed

34.

A. Svare, T.I. Nilsen, B.O. Asvold, S. Forsmo, B. Schei, T. Bjoro, A. Langhammer, Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway. Eur. J. Endocrinol. 169(6), 845–852 (2013). https://doi.org/10.1530/eje-13-0546 CrossRefPubMed

35.

H.M. Noh, Y.S. Park, J. Lee, W. Lee, A cross-sectional study to examine the correlation between serum TSH levels and the osteoporosis of the lumbar spine in healthy women with normal thyroid function. Osteoporos. Int. 26(3), 997–1003 (2015). https://doi.org/10.1007/s00198-014-2906-z CrossRefPubMed

36.

L.Y. Wang, A.W. Smith, F.L. Palmer, R.M. Tuttle, A. Mahrous, I.J. Nixon, S.G. Patel, I. Ganly, J.A. Fagin, L. Boucai, Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid 25(3), 300–307 (2015). https://doi.org/10.1089/thy.2014.0287 CrossRefPubMedPubMedCentral

37.

D. Segna, D.C. Bauer, M. Feller, C. Schneider, H.A. Fink, C.E. Aubert, T.H. Collet, B.R. da Costa, K. Fischer, R.P. Peeters, A.R. Cappola, M.R. Blum, H.A. van Dorland, J. Robbins, K. Naylor, R. Eastell, A.G. Uitterlinden, F. Rivadeneira Ramirez, A. Gogakos, J. Gussekloo, G.R. Williams, A. Schwartz, J.A. Cauley, D.A. Aujesky, H.A. Bischoff-Ferrari, N. Rodondi, Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. J. Intern. Med. 283(1), 56–72 (2018). https://doi.org/10.1111/joim.12688 CrossRefPubMed

38.

C.D. Wirth, M.R. Blum, B.R. da Costa, C. Baumgartner, T.H. Collet, M. Medici, R.P. Peeters, D. Aujesky, D.C. Bauer, N. Rodondi, Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis. Ann. Intern. Med. 161(3), 189–199 (2014). https://doi.org/10.7326/m14-0125 CrossRefPubMedPubMedCentral

39.

P. Vestergaard, L. Mosekilde, Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid 13(6), 585–593 (2003). https://doi.org/10.1089/105072503322238854 CrossRefPubMed

40.

D.S. Cooper, B. Biondi, Subclinical thyroid disease. Lancet 379(9821), 1142–1154 (2012). https://doi.org/10.1016/s0140-6736(11)60276-6 CrossRefPubMed

41.

D.S. Ross, R.M. Neer, E.C. Ridgway, G.H. Daniels, Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with l-thyroxine. Am. J. Med. 82(6), 1167–1170 (1987). https://doi.org/10.1016/0002-9343(87)90219-1 CrossRefPubMed

42.

R. Baliram, L. Sun, J. Cao, J. Li, R. Latif, A.K. Huber, T. Yuen, H.C. Blair, M. Zaidi, T.F. Davies, Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J. Clin. Investig. 122(10), 3737–3741 (2012). https://doi.org/10.1172/jci63948 CrossRefPubMed

43.

J. Foldes, G. Tarjan, M. Szathmari, F. Varga, I. Krasznai, C. Horvath, Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin. Endocrinol. 39(5), 521–527 (1993). https://doi.org/10.1111/j.1365-2265.1993.tb02403.x CrossRef

44.

A.H. Mudde, A.J. Houben, A.C. Nieuwenhuijzen Kruseman, Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin. Endocrinol. 41(4), 421–424 (1994). https://doi.org/10.1111/j.1365-2265.1994.tb02571.x CrossRef

45.

J. Faber, I.W. Jensen, L. Petersen, B. Nygaard, L. Hegedus, K. Siersbaek-Nielsen, Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin. Endocrinol. 48(3), 285–290 (1998). https://doi.org/10.1046/j.1365-2265.1998.00427.x CrossRef

46.

Y. Miyauchi, Y. Sato, T. Kobayashi, S. Yoshida, T. Mori, H. Kanagawa, E. Katsuyama, A. Fujie, W. Hao, K. Miyamoto, T. Tando, H. Morioka, M. Matsumoto, P. Chambon, R.S. Johnson, S. Kato, Y. Toyama, T. Miyamoto, HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc. Natl Acad. Sci. USA 110(41), 16568–16573 (2013). https://doi.org/10.1073/pnas.1308755110 CrossRefPubMed

47.

T. Miyamoto, Mechanism underlying post-menopausal osteoporosis: HIF1alpha is required for osteoclast activation by estrogen deficiency. Keio J. Med. 64(3), 44–47 (2015). https://doi.org/10.2302/kjm.2015-0003-RE CrossRefPubMed

48.

J. Foldes, P. Lakatos, J. Zsadanyi, C. Horvath, Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism. Eur. J. Endocrinol. 136(3), 277–281 (1997). https://doi.org/10.1530/eje.0.1360277 CrossRefPubMed

49.

C. Cormier, J.C. Souberbielle, A. Kahan, DHEA in bone and joint diseases. Jt. Bone Spine Rev. Rhum. 68(6), 588–594 (2001). https://doi.org/10.1016/s1297-319x(01)00327-x CrossRef

50.

C.M. Gordon, J. Glowacki, M.S. LeBoff, DHEA and the skeleton (through the ages). Endocrine 11(1), 1–11 (1999). https://doi.org/10.1385/endo:11:1:1 CrossRefPubMed

51.

S. Zhou, J. Glowacki, Dehydroepiandrosterone and bone. Vitam. Hormones 108, 251–271 (2018). https://doi.org/10.1016/bs.vh.2018.01.005 CrossRef

52.

S. Liu, H. Ishikawa, F.J. Li, Z. Ma, K. Otsuyama, H. Asaoku, S. Abroun, X. Zheng, N. Tsuyama, M. Obata, M.M. Kawano, Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma. Cancer Res. 65(6), 2269–2276 (2005). https://doi.org/10.1158/0008-5472.can-04-3079 CrossRefPubMed

Titel: Effect of subclinical hyperthyroidism on osteoporosis: A meta-analysis of cohort studies
verfasst von: Ningning Xu
Yaxian Wang
Yuying Xu
Lishan Li
Jiaqi Chen
Xudong Mai
Jie Xu
Zhen Zhang
Rui Yang
Jia Sun
Hong Chen
Rongping Chen
Publikationsdatum: 23.03.2020
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02259-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery

Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma

Evaluation of endocrine complications in beta-thalassemia intermedia (β-TI): a cross-sectional multicenter study

Effect of type 2 diabetes and antihyperglycemic drug therapy on signs of tumor invasion in papillary thyroid cancer

Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study